| topotecan / Generic mfg. |
NCT01630018: Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial |
|
|
| Completed | 2b | 141 | RoW | Topotecan, Hycamtin inj., Belotecan, Camtobell inj. | Chong Kun Dang Pharmaceutical | Epithelial Ovarian Cancer | 06/14 | 06/14 | | |
NCT00003944: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
|
|
| Completed | 2 | 3 | US | filgrastim, carboplatin, cyclophosphamide, paclitaxel, topotecan hydrochloride, peripheral blood stem cell transplantation | Fox Chase Cancer Center, National Cancer Institute (NCI) | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer | 12/99 | 02/03 | | |
NCT00004060: Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer |
|
|
| Completed | 2 | | US | exatecan mesylate | Daiichi Sankyo, Inc. | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | 09/00 | 09/00 | | |
NCT00004221: Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer |
|
|
| Terminated | 2 | 12 | US | Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Filgrastim, Filgrastim XM02, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tbo-filgrastim, Tevagrastim, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplantation, Topotecan Hydrochloride, Hycamptamine, Hycamtin, SKF S-104864-A, Topotecan HCl, topotecan hydrochloride (oral) | Gynecologic Oncology Group, National Cancer Institute (NCI) | Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Undifferentiated Ovarian Carcinoma | 02/02 | | | |
NCT00005051: Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer |
|
|
| Completed | 2 | | US | carboplatin, cisplatin, paclitaxel, topotecan hydrochloride | NYU Langone Health, National Cancer Institute (NCI) | Ovarian Cancer | 03/03 | | | |
NCT00046800: Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer |
|
|
| Completed | 2 | 80 | US, Europe | OSI-211 (Liposomal Lurtotecan) | Astellas Pharma Inc, OSI Pharmaceuticals | Ovarian Neoplasms | | 03/03 | | |
NCT00003065: Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix |
|
|
| Completed | 2 | 25 | US | filgrastim, paclitaxel, topotecan hydrochloride | Herbert Irving Comprehensive Cancer Center | Cervical Cancer | | 02/04 | | |
NCT00014690: ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
|
|
| Completed | 2 | | US | plevitrexed, topotecan hydrochloride | AstraZeneca | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | | 02/04 | | |
NCT00061308: Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer |
|
|
| Completed | 2 | 75 | US, Canada | Topotecan, Gemcitabine | GlaxoSmithKline | Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer | 09/04 | | | |
NCT00113789: Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer |
|
|
| Completed | 2 | 21 | US | PI Discretion | Amgen | Ovarian Cancer | 04/05 | 04/05 | | |
NCT00072267: UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
|
|
| Completed | 2 | | Canada | 7-hydroxystaurosporine, topotecan hydrochloride | University Health Network, Toronto, National Cancer Institute (NCI) | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | 04/05 | | | |
NCT00193297: Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma |
|
|
| Completed | 2 | 50 | US | Topotecan, Paclitaxel, Carboplatin | SCRI Development Innovations, LLC, GlaxoSmithKline | Ovary Cancer | 06/05 | 06/06 | | |
NCT00003732: Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer |
|
|
| Completed | 2 | 80 | Europe | carboplatin, paclitaxel, topotecan hydrochloride | Rigshospitalet, Denmark | Ovarian Cancer | | 09/05 | | |
NCT00217555: Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
|
|
| Completed | 2 | | US | gemcitabine hydrochloride, topotecan hydrochloride | Fred Hutchinson Cancer Center, National Cancer Institute (NCI) | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer | 02/06 | | | |
NCT00097019: A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed |
|
|
| Completed | 2 | 53 | NA | bevacizumab | Genentech, Inc. | Ovarian Cancer | 05/06 | 05/06 | | |
NCT00276796: Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer |
|
|
| Completed | 2 | 66 | US | cisplatin, paclitaxel, topotecan hydrochloride | Gynecologic Oncology Group, National Cancer Institute (NCI) | Cervical Cancer | 01/07 | | | |
NCT00231855: Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers |
|
|
| Completed | 2 | 31 | US | Topotecan and Taxotere | Montefiore Medical Center, Sanofi, GlaxoSmithKline | Ovarian Neoplasms, Uterine Neoplasms | | 03/07 | | |
NCT00314678: Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer |
|
|
| Completed | 2 | 40 | US | Topotecan, Cisplatin, Paclitaxel | John P. Fruehauf, GlaxoSmithKline | Epithelial Ovarian Cancer, Primary Peritoneal Cancer | | 04/07 | | |
ERBUS, NCT00518193: Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix |
|
|
| Terminated | 2 | 44 | Europe | ERBITUX | ARCAGY/ GINECO GROUP | Cervix Cancer | 07/07 | 09/08 | | |
NCT00267488: Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer |
|
|
| Completed | 2 | 70 | US, Canada, Europe | topotecan | GlaxoSmithKline | Neoplasms, Endometrial, Endometrial Cancer | 12/07 | 12/07 | | |
| Completed | 2 | 218 | US, Canada, Europe, RoW | Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Sanofi, Regeneron Pharmaceuticals | Neoplasms, Cancer of the Ovary | 04/08 | 03/10 | | |
NCT00316173: Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer |
|
|
| Completed | 2 | 77 | US, Canada | topotecan, CARBOPLATIN | GlaxoSmithKline | Ovarian Cancer, Neoplasms, Ovarian | 01/09 | 03/09 | | |
NCT00189566: Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse |
|
|
| Completed | 2 | 165 | Europe | Paclitaxel, Topotecan, Carboplatin | ARCAGY/ GINECO GROUP | Ovarian Cancer, Fallopian Tube Cancer, Malignant Tumor of Peritoneum | | 04/09 | | |
NCT00087126: Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer |
|
|
| Completed | 2 | 27 | US | topotecan hydrochloride | Gynecologic Oncology Group, National Cancer Institute (NCI) | Cervical Cancer | 01/10 | | | |
NCT00343044: Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers |
|
|
| Completed | 2 | 40 | US | Topotecan, Hycamtin, Bevacizumab, Avastin | Benaroya Research Institute, GlaxoSmithKline, Genentech, Inc. | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 01/10 | 08/11 | | |
| Completed | 2 | 81 | US | topotecan hydrochloride | Gynecologic Oncology Group, National Cancer Institute (NCI) | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | 01/11 | | | |
NCT00313612: Oxaliplatin and Topotecan in Advance Ovarian Cancer |
|
|
| Terminated | 2 | 39 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, topotecan, hycamptamine, Hycamtin, SKF S-104864-A, TOPO | National Cancer Institute (NCI) | Recurrent Ovarian Epithelial Cancer | 05/11 | 12/12 | | |
NCT01003938: Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer |
|
|
| Terminated | 2 | 6 | US | Topotecan, Topotecan hydrochloride, Hycamtin, Erlotinib, Tarceva | NYU Langone Health, OSI Pharmaceuticals | Ovarian Cancer | 09/12 | 12/12 | | |
NCT00548418: Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer |
|
|
| Completed | 2 | 27 | US | Topotecan, Hycamtin, Cisplatin, CDDP, Platin, Bevacizumab, Avastin | Washington University School of Medicine, GlaxoSmithKline, Genentech, Inc. | Cervical Cancer | 12/12 | 12/12 | | |
NCT01017809: Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer |
|
|
| Withdrawn | 2 | 0 | US | Aprepitant, Emend | NYU Langone Health | Ovarian Cancer | 12/12 | 12/13 | | |
NCT00170677: Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer |
|
|
| Completed | 2 | 194 | Europe | Topotecan | North Eastern German Society of Gynaecological Oncology | Ovarian Cancer | 01/13 | 01/13 | | |
| Completed | 2 | 110 | Europe | Paclitaxel, Gemcitabine, Topotecan, Pegylated liposomal doxorubicin (PLD), BI 6727 | Boehringer Ingelheim | Ovarian Neoplasms | 06/14 | 06/14 | | |
| Completed | 2 | 174 | Europe | Sorafenib, Nexavar® | JSehouli | Ovarian Cancer | 02/15 | 02/15 | | |
|
NCT02569957: Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
|
|
| Terminated | 2 | 1 | US | Topotecan Hydrochloride, Hycamtin, Acetylcysteine, N-acetylcysteine, N-acetyl-L-cysteine (NAC) | Sidney Kimmel Cancer Center at Thomas Jefferson University, National Institutes of Health (NIH) | Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma | 06/16 | 10/17 | | |
| Terminated | 2 | 22 | Europe | DCVAC/OvCa, Standard of Care (Paclitaxel or topotecan or doxorubicin), Paclitaxel, topotecan, doxorubicin | SOTIO a.s. | Epithelial Ovarian Carcinoma | 08/16 | 08/16 | | |
NCT02348398: Phase II Study of Pazopanib and Topotecan in Cervical Cancer |
|
|
| Withdrawn | 2 | 0 | US | Pazopanib, GW786034, Topotecan, Hycamtin, Phone Call | M.D. Anderson Cancer Center, GlaxoSmithKline | Cervical Cancer | 08/19 | | | |
NCT00003297: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer |
|
|
| Completed | 1/2 | 50 | US | mitoxantrone hydrochloride, thiotepa, topotecan hydrochloride, peripheral blood stem cell transplantation | Georgetown University, National Cancer Institute (NCI) | Ovarian Cancer | 01/01 | 01/01 | | |
NCT00005612: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer |
|
|
| Terminated | 1/2 | 3 | US | filgrastim, carboplatin, cyclophosphamide, etoposide, paclitaxel, topotecan hydrochloride, peripheral blood stem cell transplantation | H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI) | Ovarian Cancer | 02/04 | 02/04 | | |
NCT00179712: Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma |
|
|
| Completed | 1/2 | 60 | US | CC-5013, topotecan | Celgene Corporation, Prologue Research International | Ovarian Cancer | | 11/06 | | |
NCT00526799: Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer |
|
|
| Terminated | 1/2 | 30 | US | Sorafenib, Topotecan | Daniela Matei, MD, Bayer, Hoosier Cancer Research Network | Ovarian Cancer | 01/10 | 08/10 | | |
NCT00170625: Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer |
|
|
| Completed | 1/2 | 28 | Europe | Hycamtin | North Eastern German Society of Gynaecological Oncology | Ovarian Cancer | 05/10 | 09/10 | | |
| Completed | 1/2 | 12 | Europe | carboplatin, topotecan hydrochloride | ARCAGY/ GINECO GROUP | Cervical Cancer | 05/11 | | | |
NCT01076400 / 2009-017054-12: A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008) |
|
|
| Terminated | 1/2 | 7 | NA | adavosertib, MK-1775, Topotecan, Cisplatin, Placebo to adavosertib | Merck Sharp & Dohme LLC | Cervical Cancer | 06/11 | 06/11 | | |
NCT00429559: Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma |
|
|
| Completed | 1/2 | 31 | Europe | Hycamptin, Topotecan, Gemcitabine, Gemzar | Hellenic Oncology Research Group, University Hospital of Crete | Ovarian Cancer | 07/11 | 07/11 | | |
| Completed | 1/2 | 22 | Europe | Veliparib, Topotecan | Vejle Hospital, Abbott | Ovarian Cancer | 01/15 | 02/15 | | |
